Crystalline monoclonal antibodies for subcutaneous delivery

Therapeutic applications for mAbs have increased dramatically in recent years, but the large quantities required for clinical efficacy have limited the options that might be used for administration and thus have placed certain limitations on the use of these agents. We present an approach that allows for s.c. delivery of a small volume of a highly concentrated form of mAbs. Batch crystallization of three Ab-based therapeutics, rituximab, trastuzumab, and infliximab, provided products in high yield, with no detectable alteration to these proteins and with full retention of their biological activity in vitro. Administration s.c. of a crystalline preparation resulted in a remarkably long pharmacokinetic serum profile and a dose-dependent inhibition of tumor growth in nude mice bearing BT-474 xenografts (human breast cancer cells) in vivo. Overall, this approach of generating high-concentration, low-viscosity crystalline preparations of therapeutic Abs should lead to improved ease of administration and patient compliance, thus providing new opportunities for the biotechnology industry.

[1]  A. Vølund,et al.  Insulin analogs with improved pharmacokinetic profiles. , 1999, Advanced drug delivery reviews.

[2]  C. Perry,et al.  Infliximab: an updated review of its use in Crohn's disease and rheumatoid arthritis. , 2002, BioDrugs.

[3]  L. Norton,et al.  Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. , 1998, Cancer research.

[4]  A. McPherson,et al.  Chimeric human-simian anti-CD4 antibodies form crystalline high symmetry particles. , 2000, Journal of structural biology.

[5]  E. Ward,et al.  FcRn: the MHC class I-related receptor that is more than an IgG transporter. , 1997, Immunology today.

[6]  T. Sauerbruch,et al.  Mechanism of cytotoxicity induced by chimeric mouse human monoclonal antibody IDEC-C2B8 in CD20-expressing lymphoma cell lines. , 2000, Cellular immunology.

[7]  J. Hainsworth Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma: Interim follow-up of a multicenter phase II trial. , 2002, Seminars in oncology.

[8]  C. Barbas,et al.  Crystallization and preliminary structure determination of an intact human immunoglobulin, b12: an antibody that broadly neutralizes primary isolates of HIV-1. , 2001, Acta crystallographica. Section D, Biological crystallography.

[9]  L. J. Harris,et al.  Comparison of intact antibody structures and the implications for effector function. , 1999, Advances in immunology.

[10]  J. Poen,et al.  Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene. , 1999, Cancer research.

[11]  W. Nashabeh,et al.  Carbohydrate analysis of a chimeric recombinant monoclonal antibody by capillary electrophoresis with laser-induced fluorescence detection. , 1999, Analytical chemistry.

[12]  M. Navia,et al.  Protein Crystals as Novel Catalytic Materials. , 2001, Angewandte Chemie.

[13]  B. Leyland-Jones,et al.  Role of Herceptin® in Primary Breast Cancer: Views from North America and Europe , 2001, Oncology.

[14]  G. Kollias,et al.  The mouse/human chimeric monoclonal antibody cA2 neutralizes TNF in vitro and protects transgenic mice from cachexia and TNF lethality in vivo. , 1995, Cytokine.

[15]  B. Shenoy,et al.  Stability of crystalline proteins. , 2001, Biotechnology and bioengineering.

[16]  H. Merkle,et al.  Diamonds in the rough: protein crystals from a formulation perspective. , 2001 .